

# Quarterly Report

30 September 2009

A woman with short brown hair, wearing a white lab coat, is smiling and holding a large white sign. The sign contains the text: "EINFACH GUT STATT KOMPLIZIERT! DAS NEUE KLINIK-INFORMATION-SYSTEM VON NEXUS." The background is a plain, light-colored wall.

**EINFACH GUT  
STATT KOMPLIZIERT!**  
DAS NEUE KLINIK-INFORMATION-SYSTEM  
VON NEXUS.

# Letter to Our Stockholders

Dear Stockholders,

During the third quarter of 2009, we were able to confirm the positive development of the first 6 months and even better it in part. It is not only the greatly increased trading figures that are currently impressive, but also the interesting success we have had in securing orders during the last few months at home and abroad. In the current restrained market environment, we are very proud of this development. It means that we can continue our long-term upwards trend without interruption.

2

The introduction of our new development NEXUS / KIS to the market is currently the outstanding topic at NEXUS. We are convinced that we have realised a very important innovation in our sector with the approach of the NEXUS / KIS solution in terms of concept and contents. Not only do we set standards with respect to up-to-dateness and technology with our system, it has also become probably one of the most comprehensive products on the market regarding its function scope. NEXUS / KIS now covers virtually all clinical and administrative processes, which can be supported digitally in hospitals. And we don't limit ourselves to the main processes, such as documentation of surgery or logistics, but also offer our customers standardised mapping of special processes on the basis of a common technology platform, such as the mapping of the neurological rehabilitation treatments or the planning, documentation and equipment interfacing for brachytherapies. The clear

and modern structure of our solution also means that the demands on and possibilities of a clinical information system become considerably more transparent to existing and prospective customers. The picture that all those involved have of clinical information systems is slowly becoming clearer and the diffuse areas are becoming resolved. An important condition for successfully introducing CIS projects, where the customers expectations coincide with the vendor's possibilities. The current market response confirms to us that the NEXUS / KIS approach is the right one.

## Highlights Q3 - 2009 Business development

- + Strong increase in sales and profits
- + Launch of product NEXUS / KIS
- + First large orders already shortly after market introduction
- + Integration of EDS Healthcare Group

**Existing and prospective customers, whom we were able to show our product, were convinced and the first orders we received – in particular the order for 12 sites of VITOS GmbH – speak for themselves.**

In addition to these product-related topics we have strongly driven forwards the integration of the recently acquired healthcare group of EDS Schweiz during the last quarter and linked it to NEXUS Switzerland by organisational means. Thanks to the integration project, the Swiss organisation is being strengthened markedly, both in terms of content and technology – a situation that we can use to further expand our market position in Switzerland over the next few months.

During the last few months, we have continued to focus clearly on customer projects, which was a great challenge to our organisation. We have realised the live operation of our overall solution in the Canton St. Gallen, in three regions in Saudi Arabia, in Vaduz and at a further 8 sites in Germany. In addition, we have won numerous new projects in radiology and pathology, on which we have been working intensively over the last few months. The introductions have all gone very smoothly; this was not a matter of course either, considering the size, complexity and regional diversity of the projects.

We were able to continue the unbroken positive development of the last 9 years in terms of sales and profits. Sales increased during the first nine months by approx. 21.0 % from EUR 23.9 million to EUR 29.0 million and the EBITDA improved by around 31 % to EUR 5.4 million.

The **Healthcare Software segment** was strong once again and achieved an increase of **26.1 % at around EUR 25.8 million** during this period (Q3 2008: EUR 24.0 million). The profits developed positively accordingly. The **Group profits before tax** increased by **39 %** from EUR 1.2 million **to around EUR 1.7 million**. At **KEUR 2,314**, the cash flow exceeded that of the previous year by approx. 20 %.

**The good trading figures for the third quarter prove that we are also able to maintain our position and continue our development in a difficult economic environment.**

In the fourth quarter, the challenge will be to continue this trend and to achieve the set targets regarding incoming orders and project implementation. We shall also need to keep an eye on the long-term development of our company and make preparations for the next few years.

With the introduction of NEXUS / KIS to the market, we have taken an essential step for the future orientation of the company and the first market successes are very promising. There are various indications that we shall be able to use our good market position and our excellent technology to continue our successes. There will be considerable challenges for our company in the coming periods, which we shall have to handle: Building on the current good foundation, we shall do our utmost to continue the excellent development of the last few years.

Sincerely,



Dr. Ingo Behrendt  
CEO - NEXUS AG




# Innovations: NEXUS / PORTAL

Current developments in the German health care system are characterized by increasingly close cooperation between service suppliers. With the help of new treatment cooperation measures such as disease management programs, the establishment of medical care centers and the conclusion of integrated care contracts, an attempt is being undertaken to counter increasing cost pressures. Intersectoral communication is becoming increasingly important in this.

4

Cooperation in these treatment forms requires increasingly detailed synchronization and interaction between the service suppliers with the consequence of increasingly intensive exchanges of information. The new product NEXUS / PORTAL, does justice to this need for support in obtaining information. It provides initial access to the digital patient information of hospitals. The special feature of the Portal solution is that it can be integrated into the existing Internet solutions of hospitals. NEXUS took analyses and survey results of portal software users into consideration in product development; the objectives of the user groups were primary.



Integration into a referral portal provides essential advantages both to referring doctors and treating hospitals and consequently patients. An Internet-based solution, which has a link to a Hospital Information System, guarantees the referring doctor simplification of his/her work without time-consuming software installation. At the same time, it guarantees to all involved in the treatment process that they can really access the most up-to-date patient data. Hospital staff can provide treatment using their customary HIS without a change of media and have the required preliminary information, which the referring doctor supplied to them. The upper chart shows the welcome page of NEXUS / PORTAL out of a referring doctors perspective.

**The referring doctors, i.e., especially general practitioners, can retrieve doctors' letters, OP reports and findings quickly and treat their patients well-informed after their hospital stays.**

The advantages for the patients, hospitals and referring doctors are obvious:

- + The admitting hospital has all preliminary information regarding the case and can minimize conducting the same examinations twice.
- + The treatment process can be set and optimized at an early stage.
- + A seamless transition to those providing post-discharge treatment is ensured.
  
- + The webpages of the hospital become an information portal for doctors and patients.
- + Referring doctors can develop stronger relations with the hospital.
- + Faster access to patient information (protected area).
- + Coordinating scheduling for outpatient clinics, OP and follow-up appointments becomes easier.
- + Case history information from the outpatient clinic or other preliminary examinations is available online.

NEXUS is providing another building block on the way to a digital hospital with this product.

# NEXUS in the environment of Financial and Health markets



The value of NEXUS stocks weren't able to abstract to the downside trend of the market. After a sideways tendency price fell from apporx. 2.70 € to 2.40 € from June till the end of July. At the beginning of August the performance rebounded slightly to 2.50 €, until it fell again at end of August. Worldwide beginning financial crisis at October hasn't treated price of shares well, so the price fell below 2 €-limit on the beginning of November. Even relatively better performance as TecDax is cold comfort.

## Finance- and Event schedule 2009/10 (status quo: November `09)

### FINANCE SCHEDULE

German equity forum, Frankfurt (D)	November 10th
Annual Report 2009	March 29th, 2010

### EVENT AND TRADE FAIR SCHEDULE

MEDICA, Düsseldorf (D)	18 - 21 November
DGPPN, Berlin (D)	25 - 28 November
Arab Health 2010, Dubai (UAE)	25 - 28 January 2010

5

## Decisions for NEXUS-solutions 2008

- + Ortenau Klinikum, Achern
- + Erzgebirgsklinikum, Annaberg
- + Kreiskliniken, Altötting-Burghausen
- + Klinikum, Aschaffenburg
- + Klinik Niedersachsen, Bad Nenndorf
- + Lungenklinik, Ballenstedt
- + Krankenhaus Maria Hilf, Bergheim
- + Deutsches Herzzentrum - Pathologie, Berlin
- + Park-Klinik Weißensee, Berlin
- + Johanniter-Krankenhaus, Bonn
- + Uniklinikum, Essen
- + Krankenhaus Maria Hilf, Gangelt
- + Clemenshospital, Geldern
- + Institut für Pathologie, Geldern
- + Radiologische Praxis am Wollhaus, Heilbronn
- + Pathologische Gemeinschaftspraxis, Kaufbeuren
- + Oberallgäu-Klinikum, Kempten
- + Radiologisches Institut, Koblenz
- + Psychiatrisches Fachkrankenhaus, Kropp
- + Vincentius-Krankenhaus, Landau
- + Universitätsklinikum Schleswig-Holstein, Lübeck
- + Städtische Kliniken, Mönchengladbach
- + Klinikum, Passau
- + St. Josefs-Krankenhaus, Potsdam
- + Klinikum am Steinberg, Reutlingen
- + Marienkrankenhaus, Schwerte
- + St. Vincentius Krankenhaus, Speyer
- + Robert-Bosch-Krankenhaus - Pathologie, Stuttgart
- + Caritas Trägergesellschaft, Trier
- + Fachklinik für Psychiatrie und Psychotherapie, Zülpich
- + Hospital Citadelle, Liege (BE)
- + Unispital, Bern (CH)
- + Clinica Santa Chiara, Locarno (CH)
- + Hirslanden Klinik, Zurich (CH)

# Sales Increase in the 3rd Quarter

During the first three quarters of 2009, the group sales of the NEXUS Group were increased by 21.0 % from KEUR 23,988 to KEUR 29,030.

Once more, the strong sales increase was down to segment „**Healthcare Software**“. Here, sales rose year on year from KEUR 20,425 to **KEUR 25,766 (+26.1 %)**. The good development was due to the introduction of numerous new software products and increased sales to existing customers.


6

At **KEUR 3,265** (previous year KEUR 3,563), the sales of the „**Healthcare Service**“ segment were lower than last year's figure (-8 %). Here, the targets were not achieved.

During the **third quarter**, total **sales of KEUR 10,201** were achieved, therefore approx. 18.3 % more than in the previous year. This means that the Healthcare Software segment achieved an increase of 24.4 % from 7,313 (Q3 2008) to KEUR 9,098 (Q3 2009), while the Healthcare Service segment achieved 16 % lower sales of KEUR 1,103.

The **proportion of sales abroad** was **35.5 %** for the key date and was therefore at the level of the previous year (35.8 %). The continuing high proportion of sales in the international market is due mainly to projects in the **USA, in the Middle Eastern region and in Switzerland**.

**One point to be mentioned specifically with respect to the first 9 months is the increase in sales in the area of Clinical Information Systems (CIS) in Germany and in Switzerland.**



Sales by regions	01/01/ -	01/01/ -	Δ in %	07/01/ -	07/01/ -	Δ in %
	09/30/08	09/30/09		09/30/08	09/30/09	
	KEUR	KEUR		KEUR	KEUR	
Germany	15,409	18,724	21.5	5,612	6,625	18.1
Switzerland	5,777	6,946	20.2	1,495	2,716	81.7
Austria	569	651	14.4	176	222	26.1
Italy	85	141	65.9	28	66	135.7
Rest of Europe / USA	1,302	1,160	-10.9	922	24	-97.4
Arabian region	846	1,408	66.4	393	548	39.4
<b>Total</b>	<b>23,988</b>	<b>29,030</b>	<b>21.0</b>	<b>8,626</b>	<b>10,201</b>	<b>18.3</b>

Highlights Q3 - 2009	
Group sales and Result	
+	Increase in EBITDA by 31 % to EUR 5.4 million
+	21.0 % increase in sales to EUR 29.0 million
+	26.1 % increase in sales in segment Healthcare Software to EUR 25,8 million
+	Operative Cash Flow increased by 96.2 % to TEUR 4,540

Sales by divisions	01/01/ -	01/01/ -	Δ in %	07/01/ -	07/01/ -	Δ in %
	09/30/08	09/30/09		09/30/08	09/30/09	
	KEUR	KEUR		KEUR	KEUR	
Healthcare Software	20,425	25,765	26.1	7,313	9,098	24.4
Healthcare Service	3,563	3,256	-8.4	1,313	1,103	-16.0
<b>Total</b>	<b>23,988</b>	<b>29,030</b>	<b>21.0</b>	<b>8,626</b>	<b>10,201</b>	<b>18.3</b>

# Results in the First three Quarters 2009

The profit key figures developed positively throughout the first three quarters. The group results before tax increased by around 39 % to KEUR 1,654 during this period (Q3 2009 KEUR 1,190).

The **EBITDA** reached **KEUR 5,380 (+ 30,5 %)** compared to 4,124 (Q3 2008). The **result after tax** suffered from a higher reduction of deferred taxes (KEUR 267.0) than in the previous year, but increased all the same by **17.3 % to KEUR 1,370** (Q3-2008 KEUR 1,168).




With an overall result of **KEUR 552** (Q3-2008 KEUR 728), segment „**Healthcare Service**“ was markedly below the previous year's level, while segment „**Healthcare Software**“ was higher at **KEUR 1,103** (Q3 2008 KEUR 440).

Compared to the previous year, the **operative cash flow** increased by KEUR 378 from KEUR 2,314 **to KEUR 4,540 (+96,2 %)**.

The cash flow from investment activities was KEUR -1.961 compared to KEUR -978 (Q3-2008). The acquisition of the healthcare division of EDS-Schweiz AG, which was partly financed by selling securities, represented the main investment here.

**The NEXUS Group retains a high level of liquid funds of KEUR 9,625 (12/31/2008: KEUR 9,500).**

Die Anzahl der Mitarbeiter stieg im Berichtszeitraum von 351 (Q3-2008) auf aktuell 359. Davon waren 321 im Bereich Healthcare Software und 38 in der Sparte Healthcare Service beschäftigt.



# NEXUS Group informationen and Outlook

## Directors Holdings

The Director's Holdings of the supervisory board and the executive board were as follows on September 30, 2009 in comparison to the previous year:

## Opportunities and Risks

The positive development during the current year is underpinned by a stable inflow of orders and an improved market position. Due to increasing demand and good acceptance of our system, we are foreseeing clear potential in the German CIS market, but also in the international markets. These potentials might materialise during the coming months. At the same time, there are considerable challenges from existing projects and development projects, which might jeopardise this trend. The same applies to new or existing competitors. We consider the integration of the acquired companies a particular continuing challenge. Here, we need to drive the technological and organisational integration forwards

## Outlook

The position of NEXUS is currently distinctly stable and the development of the company very positive. However, in the turbulent economic arena, we are looking at a quickly changing environment, which is currently difficult to assess. More than ever we must make efforts to organise a steady and speedy adaptation process in our own company to ensure long-term success. It is therefore essential that we offer a modern system to win further projects in the market. That is the only way to continue the growth of the last few years. With this in mind, we have introduced our new product „NEXUS / KIS“ into the market and advertised it strongly with a marketing offensive. The first successful orders are already coming in, providing us with a positive look to the future.

## ACCOUNTING AND VALUATION METHODS

This interim report from the NEXUS Group of 30 September 2009 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The regulations of IAS 34 have been observed in the interim report of 30 September 2009. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2008. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2008.

The report has not been audited.

The Group Financial Statement 2008 and the interim report of 30 September 2009 can be seen on the homepage in the Internet at: [www.nexus-ag.de](http://www.nexus-ag.de).

Directors Holdings	Number of stocks owned	Numbers of options
<b>SUPERVISORY BOARD</b>		
Dr. jur. Hans-Joachim König	81,099	0
	Prev. year: 81,099	Previous year: 0
Prof. Dr. Ulrich Krystek	0	0
	Previous year: 0	Previous year: 0
Dipl.-Betriebsw. (FH) Wolfgang Dörflinger	0	0
	Previous year: 0	Previous year: 0
Matthias Gaebler	0	0
	Previous year: 0	Previous year: 0
Erwin Hauser	15,000	0
	Previous year: 15,000	Previous year: 0
Prof. Dr. Alexander Pocsay	0	0
	Previous year: 0	Previous year: 0
<b>EXECUTIVE BOARD</b>		
Dr. Ingo Behrendt (MBA)	112,000	325,000
	Prev. year: 82,000	Prev. year: 325,000
Dipl.-Betriebsw. (FH) Ralf Heilig (MBA)	129,350	60,000
	Prev. year: 129,350	Prev. year: 60,000
Dipl.-Ing. (FH) Edgar Kuner	264,051	37,000
	Prev. year: 264,051	Prev. year: 37,000

# Facts and Figures Group P+L Account as of 09/30/2009 and 09/30/2008 (IFRS)

CONSOLIDATED PROFIT AND LOSS ACCOUNT	07/01/ - 09/30/08	07/01/ - 09/30/09	01/01/ - 09/30/08	01/01/ - 09/30/09
	KEUR	KEUR	KEUR	KEUR
1. Revenue	8,626	10,202	23,988	29,030
2. Increase / decrease in finished goods and work in progress	115	-3	79	-34
3. Other capitalized company work	873	1,109	2,724	3,062
4. Other operating income	422	207	1,012	1,647
5. Cost of materials	1,920	1,944	4,716	6,184
a) Cost of raw materials and supplies	1,475	1,404	3,471	4,419
b) Cost for purchased services	445	540	1,245	1,765
6. Personnel expenses	4,924	5,209	14,242	15,793
a) Wages and salaries	4,187	4,441	12,280	13,473
b) Social costs	737	768	1,962	2,320
7. Depreciation and amortization of fixed intangible and tangible assets	1,220	1,414	3,508	3,978
8. Other operating expenses	1,636	2,333	4,548	6,335
a) Cost of operation	455	579	1,301	1,671
b) Cost of distribution	485	623	1,291	1,504
c) Cost of administration	533	503	1,587	1,671
d) Other expenses	163	628	369	1,489
9. Other taxes	2	8	7	12
10. Expenses from associated companies	-	-	-	-
11. Other interest and similar income	67	70	434	269
12. Revenue from associated companies	0	0	1	0
13. Profit resulting from sale of other stocks	-	-	-	-
14. Depreciation of financial assets and losses resulting from the sale of assets	-	-	-	-
15. Interest payable and other similar charges	-39	-4	27	17
<b>PROFIT BEFORE TAX</b>	<b>441</b>	<b>673</b>	<b>1,190</b>	<b>1,655</b>
16. Income taxes	24	152	-22	-285
<b>ANNUAL NET PROFIT</b>	<b>465</b>	<b>521</b>	<b>1,168</b>	<b>1,370</b>
Are attributable to:				
Minority interest	7	34	-81	-80
Stockholders of parent company	458	487	1,088	1,290
Weighted average of issued shares (in thousands)	13,805	13,805	13,805	13,805
<b>ERESULT PER SHARE IN EUR (DILUTED AND UNDILUTED )</b>	<b>0.03</b>	<b>0.04</b>	<b>0.08</b>	<b>0.09</b>

# Facts and Figures

## Balance sheet as of 12/31/2008 and 09/30/2009 (IFRS)

10

<b>BALANCE SHEET AS OF 09/30/2009 (IFRS) ASSETS</b>	<b>12/31/2008</b>	<b>09/30/2009</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>LONG-TERM CAPITAL</b>		
I. Intangible assets		
1. Concessions, industrial property rights, and rights and assets as well as licenses for such rights and assets	252	1,836
2. Goodwill	11,636	11,636
3. Development costs	9,532	8,558
4. Customer Base / Technology	5,203	5,503
II. Property, plant and equipment		
1. Tenant installations	60	53
2. Other equipment, factory and office equipment	1,136	1,022
III. Financial assets		
1. Investments in associates		
2. Other tangible assets		
3. Long-term securities		
IV. Deferred taxes	3,965	3,749
<b>TOTAL LONG-TERM CAPITAL</b>	<b>32,270</b>	<b>32,570</b>
<b>SHORT-TERM CAPITAL</b>		
I. Inventories		
1. Raw materials and supplies	48	20
2. Work in progress	103	69
3. Finished goods	128	297
4. Down payment made		
II. Receivables and other assets		
1. Trade receivables	9,489	12,846
2. Receivables from associated companies	6	0
3. Other assets	875	400
4. Tax refund claims	450	292
5. Other assets	2,414	2,651
III. Derivative Financial Instruments	129	216
IV. Securities	5,319	2,895
V. Cash and cash equivalents	4,141	6,730
<b>TOTAL SHORT-TERM CAPITAL</b>	<b>23,102</b>	<b>26,416</b>
<b>TOTAL ASSETS</b>	<b>55,372</b>	<b>58,986</b>

# Facts and Figures

## Balance sheet as of 12/31/2008 and 09/30/2009 (IFRS)

<b>BALANCE SHEET AS OF 09/30/2009 (IFRS) EQUITY AND LIABILITIES</b>	<b>12/31/2008</b>	<b>09/30/2009</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>EQUITY</b>		
I. Subscribed capital	13,805	13,805
II. Capital reserve	39,483	39,523
III. Other reserves	-	-3
IV. Equity capital difference from currency translation	59	58
V. Valuation reserve for financial instruments	-999	-679
VI. Reserve for pensions	-72	-60
VII. Loss carry-forward	-9,503	-8,014
VIII. Annual net profit	1,488	1,290
IX. Treasury stock	-26	-27
<b>EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY</b>	<b>44,235</b>	<b>45,893</b>
Minority interest	259	351
<b>TOTAL EQUITY</b>	<b>44,494</b>	<b>46,244</b>
<b>LONG-TERM LIABILITIES</b>		
I. Pension provisions	534	525
II. Other provisions	2,112	1,977
<b>TOTAL LONG-TERM LIABILITIES</b>	<b>2,646</b>	<b>2,502</b>
<b>SHORT-TERM LIABILITIES</b>		
I. Other provisions	653	1,428
II. Bank loans	111	59
III. Received payments or orders	947	659
IV. Trade accounts payable	2,431	2,539
V. Liabilities with associated companies	-	1
VI. Tax provisions	1,016	783
VII. Other liabilities	2,477	2,962
VIII. Deferred income	597	1,812
<b>TOTAL SHORT-TERM LIABILITIES</b>	<b>8,232</b>	<b>10,240</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>55,372</b>	<b>58,986</b>

<b>CASH FLOW</b>	<b>2008</b>	<b>2009</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>1. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	1,190	1,655
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	3,508	3,978
Other expenses / income with no impact on cash	-61	-276
Profit / loss from disposal of securities	13	136
Increase / decrease in inventories	-906	-107
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	1,428	-2,965
Changes in provision	-415	569
Increase / decrease in trade accounts payable and other liabilities that cannot be allocated to investing or financing activities	-2,830	1,185
Interest paid	-27	-17
Interest payments received	371	265
Income taxes paid	-149	-118
Income taxes received	192	235
	<b>2,314</b>	<b>4,540</b>
<b>2. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Cash paid for investments in property, plant and equipment / intangible assets	-3,436	-4,238
Acquisition of consolidated companies, net of purchased cash	-963	-252
Cash receipts from disposal of securities	3,421	2,529
Cash paid for investments in securities	0	0
	<b>-978</b>	<b>-1,961</b>
<b>3. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Increase in share capital by edition of equity options	0	0
Allocation to capital reserve by edition of equity options	0	0
Amount paid for financial assets	0	0
Amount paid/receipt out for redeeming/clearing loans	-32	-52
	<b>-32</b>	<b>-52</b>
<b>4. CASH AND CASH EQUIVALENTS AT END OF FISCAL YEAR</b>		
Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	1,304	2,527
Change in currency translation adjustment	0	3
Cash and cash equivalents at beginning of fiscal year	2,390	4,141
	<b>3,694</b>	<b>6,671</b>
<b>5. COMPOSITION OF CASH AND CASH EQUIVALENTS</b>		
Cash on hand	3,847	6,730
Bank liabilities due on demand	-153	-59
	<b>3,694</b>	<b>6,671</b>

# Facts and Figures Development of Group Equity as of 09/30/2009 and 09/30/2008 (IFRS)

DEVELOPMENT OF GROUP EQUITY	SUBSCRIBED CAPITAL	CAPITAL RESERVES	OTHER PROVISIONS	EQUITY DIFFERENCE FROM CURRENCY CONVERSION	RESERVE FOR FINANCIAL INSTRUMENTS	RESERVE FOR PENSIONS	CONSOLIDATED LOSS CARRY FORWARD	CONSOLIDATED DEFICIT / PROFIT	TREASURY STOCK	EQUITY CAP , ATTRIBUTABLE TO STOCKH, OF PARENT COMPANY	MINORITY INTEREST	TOTAL EQUITY	AUTHORIZED CAPITAL
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
CONSOLIDATED EQUITY AS OF 12/31/2006	13,805	39,372	0	10	-383	-89	-10,666	1,163	-26	43,186	320	43,506	6,860
Transfer of 2007 consolidated loss to consolidated loss carry-forward							1,163	-1,163		0		0	
Total income entered directly in equity capital				42	-183	41				-100		-100	
Profit before tax 09/30/2008								1,088		1,088	-13	1,075	
Transfer to other Provisions													
OVERAL RESULT OF THE PERIOD	0	0	0	42	-183	41	0	1,088	-26	988	-13	975	
Edition of equity options to employees										0		0	
Stock-based payment		88								88		88	
CONSOLIDATED EQUITY ON 09/30/2008	13,805	39,460	0	52	-566	-48	-9,503	1,088	-26	44,262	307	44,569	6,860
CONSOLIDATED EQUITY ON 12/31/2008	13,805	39,483	0	59	-999	-72	-9,503	1,488	-26	44,235	259	44,494	6,860
Profit before tax 2008 entered directly in accumulated deficit							1,488	-1,488		0		0	
Total income entered directly in equity capital				-4	320	12				328		328	
Profit before tax 06/30/2008								1,290		1,290	92	1,382	
OVERAL RESULT OF THE PERIOD	0	0	0	-4	320	12	0	1,290	0	1,618	92	1,710	
Stock-based payment		40								40		40	
CONSOLIDATED EQUITY ON 06/30/2008	13,805	39,523	0	55	-679	-60	-8,015	1,290	-26	45,893	351	46,244	6,860

## **Declaration according to § 37y No. 1 WpHG**

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, November 10th, 2008

NEXUS AG  
Executive Board

**nexus/ag**  
*e-health solutions*

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen  
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888  
[www.nexus-ag.de](http://www.nexus-ag.de), [info@nexus-ag.de](mailto:info@nexus-ag.de)